Valeant Pharmaceuticals International is banking on people’s willingness to spend money on their looks. The Aliso Viejo-based drug maker’s made several buys of skin drug companies to build its ...

Allergan has adopted a poison pill to fend off the hostile takeover by Valeant and Bill Ackman’s Pershing Square Capital. It has given existing shareholders the right to buy sha ...

Valeant Pharmaceuticals International Inc. tumbled to a two-year low, closing out its worst month ever, after billionaire shareholder William Ackman failed to persuade investors the stock was ...

Valeant Pharmaceuticals International has forged its biggest deal since a “rebirth” of the Costa Mesa drug maker slightly more than a year ago. The company last week said it plans to buy Xcel ...

The board of Laval, Quebec, Canada-based Valeant Pharmaceuticals has launched a search for a new CEO to replace J. Michael Pearson, who has served as CEO since 2008. Here are seven things to know ...

Bausch Health agreed to pay the SEC $45 million to settle Valeant Pharmaceuticals (former name) accounting fraud schemes. Three former executives, former CEO Michael Pearson, CFO Howard Schiller and ...

TORONTO (Reuters) - Valeant Pharmaceuticals , which dropped a $5.7 billion offer for Cephalon Inc earlier this week, is talking to potential takeover targets and will pursue other large deals, its ...

(Bloomberg) Valeant Pharmaceuticals International Inc. shares slumped as Chief Executive Officer J. Michael Pearson’s defense of the drugmaker’s accounting and ethics failed to resonate with investors ...

For a few weeks in January, Valeant Pharmaceuticals' (NYSE: VRX) stock outperformed the S&P 500 index. The run didn't last long, though. Here's why Valeant's rebound quickly fizzled. The first phase ...

Image source: Walgreens Boots Alliance. What: After Walgreens Boots Alliance management reported quarterly financials and indicated a willingness to work with Valeant Pharmaceuticals to make their ...

As Valeant's largest shareholder, this fund has been hit hard on a number of fronts. With Valeant's shares down more than 70% since mid-September, the fund's once-exceptional trailing results are in ...

J. Michael Pearson, CEO of Valeant Pharmaceuticals International, a publicly-traded, multinational specialty drug company based in Laval, Quebec, is on medical leave after being diagnosed with severe ...